MSME (Udyam registered) Ministry of MSME
- Category
- Small (2024-25)
- Udyam number
- UDYAM-MH-33-0041439
U S Pharma (India) Private Limited - pharma in Mumbai, Maharashtra, India. FY 2026 financials & compliance.
Revenue · FY 2025
₹89.26 Cr
▲ 421% YoY
Net profit · FY 2025
₹8.02 Cr
Net margin 9%
EBITDA · FY 2025
₹10.56 Cr
EBITDA margin 11.8%
Authorised capital
₹15 Cr
Registered with MCA
Paid-up capital
₹2.49 Cr
Issued & subscribed
Open charges
₹12 Cr
Satisfied ₹22.43 Cr
Company age
23 yrs
Est. 2003
Directors on board
2
As per MCA filings
About U S Pharma (India) Private Limited
Data last updated:
U S Pharma (India) Private Limited is a private limited company based in Mumbai, Maharashtra, India. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 21 May 2003 and has been in existence for over 23 years.
The company is registered with the Registrar of Companies (ROC), Mumbai, under CIN U24230MH2003PTC140514. Its GSTIN is 27AAACU6722G1ZD (Maharashtra). The company holds 2 GST registrations, all of them active.
The company has an authorised share capital of ₹15 Cr and a paid-up capital of ₹2.49 Cr. It is led by directors Tapan Haresh Sanghvi and Mansi Tapan Sanghvi.
Its last annual general meeting (AGM) was held on 30 September 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at Mumbai, Maharashtra.
As per the financials filed for FY 2025, the company reported a revenue of ₹89.26 Cr, reflecting significant growth compared to the previous year. For the same year it recorded a net profit of ₹8.02 Cr (net margin 9%) and EBITDA of ₹10.56 Cr (EBITDA margin 11.8%). Revenue has grown at a compounded annual rate (CAGR) of 43% over three years and 31% over five years.
The company is associated with 1 brand: US Pharma. As per MCA filings, the company has open charges of ₹12 Cr and satisfied charges of ₹22.43 Cr on record. Court records list 3 cases involving the company, including 3 filed against it.
U S Pharma (India) Private Limited is registered as a small enterprise under the Udyam registration framework (Reg. No. UDYAM-MH-33-0041439). The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website uspharma.in.
Company details
CIN U24230MH2003PTC140514
Registration Number 140514
Incorporation Date 21 May 2003
ROC Mumbai
Listing Status Unlisted
Company Status Active
Date of Last AGM 30 September 2025
Date of Balance Sheet 31 March 2025
Compliance Status Active Compliant
MSME Classification Small
Udyam Registration UDYAM-MH-33-0041439
Recognitions & Rankings of U S Pharma (India)
Contact details
U S Pharma (India) Private Limited's registered office is in Mumbai, Maharashtra. Its website is uspharma.in. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Website
- Registered AddressFloor 2 Plot – 1076 Apte Industrial Estate Parijot House, Laxminarsingh R Papan Marg Off Dr. E Moses Road, Mumbai, Maharashtra, India – 400018
- IndustryPharma, Drug Formulation & Development
To see the full contact details of U S Pharma (India) Private Limited, buy the company report.
Comprehensive company report
U S Pharma (India) Private Limited - one report that includes everything
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included
Brands
U S Pharma (India) operates one associated brand: US Pharma. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| Pharmaceutical product manufacturing and contract services in India. | uspharma.in |
Business activity
The main business activity of U S Pharma (India) is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products |
To see the full business activity and turnover split of U S Pharma (India) Private Limited, buy the company report.
Financials of U S Pharma (India) Private Limited
FY 2025 filings availableU S Pharma (India) Private Limited reported revenue of ₹89.26 Cr (up 421% YoY) for FY 2025.
Revenue · FY 2025
₹89.26 Cr ▲ 421%
Net profit · FY 2025
₹8.02 Cr margin 9%
EBITDA · FY 2025
₹10.56 Cr margin 11.8%
Compounded Annual Growth Rate (CAGR)
Revenue CAGR growth
1 year
▲ 421%
3 years · compounded
▲ 43%
5 years · compounded
▲ 31%
EBITDA CAGR growth
3 years · compounded
▲ 51%
5 years · compounded
▲ 18%
Revenue has grown at a compounded annual rate (CAGR) of 31% over five years, including 421% growth in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | |||||
| Other Income | |||||
| Total Revenue | |||||
| Cost of Materials Consumed | |||||
| Employee Benefit Expense | |||||
| Finance Costs | |||||
| Depreciation and Amortisation | |||||
| Other Expenses | |||||
| Total Expenses | |||||
| EBITDA | ₹10.56 Cr | ||||
| Profit Before Tax | |||||
| Tax Expense | |||||
| Net Profit (PAT) | ₹8.02 Cr | ||||
| Balance Sheet | |||||
| Share Capital | |||||
| Reserves and Surplus | |||||
| Net Worth (Total Equity) | |||||
| Long-term Borrowings | |||||
| Short-term Borrowings | |||||
| Trade Payables | |||||
| Total Liabilities | |||||
| Fixed Assets | |||||
| Investments | |||||
| Inventories | |||||
| Trade Receivables | |||||
| Cash and Bank Balance | |||||
| Total Assets | |||||
Financial Ratios
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | 11.8% | ||||
| Net Profit Margin | 9% | ||||
| Return on Equity (ROE) | |||||
| Return on Capital Employed (ROCE) | |||||
| Return on Assets (ROA) | |||||
| Liquidity and Debt | |||||
| Current Ratio | |||||
| Quick Ratio | |||||
| Debt-to-Equity Ratio | |||||
| Interest Coverage Ratio | |||||
| Efficiency and Growth | |||||
| Asset Turnover | |||||
| Receivable Days | |||||
| Payable Days | |||||
| Inventory Days | |||||
| Revenue Growth | |||||
| Net Profit Growth | |||||
To see the full financial statements and ratios of U S Pharma (India) Private Limited, buy the company report.
Board of directors of U S Pharma (India) Private Limited
U S Pharma (India) has 2 current directors and 9 former directors. Current directors are listed first, with their designation and appointment date.
Current Directors
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Tapan Haresh Sanghvi | Director | 12 Dec 2014 | 11 Years 10 Months | Current |
| Mansi Tapan Sanghvi | Director | 30 Sep 2020 | 6 Years 0 Months | Current |
Peer comparison
U S Pharma (India) Private Limited is compared with the 8 companies closest to it by revenue in the Pharma industry (Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Verdant Life Sciences Private Limited | ₹89.48 Cr (FY 2025) | 6.0% | Andhra Pradesh, India | |||
| Sam Fine O Chem Limited | ₹89.46 Cr (FY 2025) | 22.0% | Rajkot, Gujarat, India | |||
| Medilux Laboratories Pvt Ltd | ₹89.42 Cr (FY 2018) | -2.0% | Indore, Madhya Pradesh, India | |||
| Evertogen Life Sciences Limited | ₹89.28 Cr (FY 2024) | 51.0% | Hyderabad, Telangana, India | |||
| U S Pharma (India) Private Limitedthis company | ₹89.26 Cr (FY 2025) | ₹8.02 Cr | 9% | 421.0% | Mumbai, Maharashtra, India | |
| Gnosis Pharmaceuticals Private Limited | ₹88.76 Cr (FY 2024) | 18.0% | New Delhi, Delhi, India | |||
| Martin & Brown Bio-Sciences Private Limited | ₹88.52 Cr (FY 2025) | 75.0% | Nalagarh, Himachal Pradesh, India | |||
| Ravian Life Science Private Limited | ₹88.41 Cr (FY 2025) | 2.0% | Haridwar, Uttarakhand, India | |||
| SRS Pharmaceuticals Private Limited | ₹88.26 Cr (FY 2025) | -10.0% | Mumbai, Maharashtra, India |
To see the full peer comparison of U S Pharma (India) Private Limited, buy the company report.
Auditor
U S Pharma (India) Private Limited is audited by R VASANT ANDHALE AND COMPANY for the financial year 2023.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| R VASANT ANDHALE AND COMPANY | FY 2023 | 135184W |
Shareholding
The shareholding of U S Pharma (India) Private Limited is on record for 5 financial years, the latest being FY 2023, split between promoters, domestic institutions, foreign institutions, public shareholders and others.
| Shareholder category | FY 2023 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|
| Promoters | |||||
| Domestic institutional investors (DII) | |||||
| Foreign institutional investors (FII) | |||||
| Public | |||||
| Others |
To see the full shareholding pattern of U S Pharma (India) Private Limited, buy the company report.
Charges & borrowings
Open charges
₹12 Cr
Satisfied charges
₹22.43 Cr
Breakdown by lending institutions
Latest charge details
| Date | Charge ID | Lender | Amount | Status | Modified or satisfied on |
|---|---|---|---|---|---|
| 29 Jul 2025 | 101142060 | Others | ₹10 Cr | Open | |
| 10 Aug 2021 | 100468592 | Sidbi | ₹2 Cr | Open | |
| 29 Oct 2022 | 100629807 | Others | ₹7 Cr | Satisfied | |
| 19 Jan 2022 | 100525067 | Others | ₹8.5 Cr | Satisfied | |
| 24 Jun 2019 | 100274050 | Others | ₹3 Cr | Satisfied |
To see the full charge records of U S Pharma (India) Private Limited, buy the company report.
Total charge records: 11 View all charges
Legal cases
U S Pharma (India) Private Limited has 3 court cases on record: 3 filed against it. All cases are disposed.
Total cases
3
Filed against the company
3
Disposed
3
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| High courts | 3 | 3 | 0 |
Cases on record (3 of 3)
| Court | Type of case | Party | Status |
|---|---|---|---|
| Bombay High Court | Court case (NMA) | Filed against the company by Sunrise Containers Ltd | Disposed |
| Bombay High Court | Court case (APP) | Filed against the company by Sunrise Containers Limited , Mumbai | Disposed |
| Bombay High Court | Company petition | Filed against the company by Sunrise Containers Limited | Disposed |
To see the full case history of U S Pharma (India) Private Limited, buy the company report.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
MSME payment delays
U S Pharma (India) Private Limited has 12 MSME Form 1 returns on record between 2019 and 2024, listing 583 overdue payments to 109 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.
Suppliers with reported dues (5 of 109)
| Supplier | Amount due | Due since | Reported on |
|---|---|---|---|
| National Capsules Private Limited | |||
| Scorpion Containers Private Limited | |||
| an individual supplier | |||
| an individual supplier | |||
| Raj Enterprises |
To see the full MSME payment records of U S Pharma (India) Private Limited, buy the company report.
Individuals and sole proprietors among the suppliers are not named.
GST
U S Pharma (India) has 2 GST registrations: 2 active.
Total GSTINs
2
Active
2
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 27AAACU6722G1ZD | Maharashtra | Active | 01 Jul 2017 |
| 06AAACU6722G1ZH | Haryana | Active | 16 Aug 2023 |
To see the full GST registrations and return filing status of U S Pharma (India) Private Limited, buy the company report.
Recent activity
U S Pharma (India) Private Limited has 11 board changes on record since 2010: 2 appointments and 9 cessations. The latest: Mansi Tapan Sanghvi ceased to be Additional Director on 31 Dec 2020.
AGM
U S Pharma (India) Private Limited last Annual general meeting of members was held on 30 Sep 2025 as per latest MCA records.
Charges
A charge registered on 29 Oct 2022 via Charge ID 100629807 with Others was fully satisfied on 06 Sep 2025.
Charges
A charge with Others amounted to Rs. 10.00 Cr with Charge ID 101142060 was registered on 29 Jul 2025.
Filing
U S Pharma (India) Private Limited has filed its annual Financial statements for the year ended 31 Mar 2025 with Roc Mumbai.
Charges
A charge with Others amounted to Rs. 7.00 Cr with Charge ID 100629807 was registered on 29 Oct 2022.
Charges
A charge registered on 19 Jan 2022 via Charge ID 100525067 with Others was fully satisfied on 02 May 2022.
Charges
A charge with Others amounted to Rs. 8.50 Cr with Charge ID 100525067 was registered on 19 Jan 2022.
Charges
A charge with Sidbi amounted to Rs. 2.00 Cr with Charge ID 100468592 was registered on 10 Aug 2021.
Charges
A charge registered on 24 Jun 2019 via Charge ID 100274050 with Others was fully satisfied on 19 Jul 2021.
Ceased
Mansi Tapan Sanghvi ceased to be Additional Director.
Ceased
Panna Haresh Sanghvi ceased to be Director.
Appointed
Mansi Tapan Sanghvi was appointed as Director.
24 earlier events are in the company report.
Frequently asked questions
U S Pharma (India) is an active private limited company based in Mumbai, Maharashtra, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 21 May 2003 (23+ years old) and is registered under CIN U24230MH2003PTC140514.
U S Pharma (India) has 2 current directors:
- Tapan Haresh Sanghvi - Director
- Mansi Tapan Sanghvi - Director
The latest financial statements of U S Pharma (India) on record with the MCA are for the year ended 31 March 2025. Its last annual general meeting was held on 30 September 2025. Year-wise statements from 2015 are in the company report.
The GSTIN of U S Pharma (India) is 27AAACU6722G1ZD, registered in Maharashtra. The company has 2 GST registrations in all, of which 2 are active. Other active GSTINs include 06AAACU6722G1ZH (Haryana).
The CIN (Corporate Identification Number) of U S Pharma (India) is U24230MH2003PTC140514. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
U S Pharma (India) has 3 court cases on record: 3 filed against it.
U S Pharma (India) was incorporated on 21 May 2003, making it 23+ years old. It is registered with the Registrar of Companies, Mumbai.
The peers of U S Pharma (India) by revenue are Verdant Life Sciences Private Limited, Sam Fine O Chem Limited, Medilux Laboratories Pvt Ltd, Evertogen Life Sciences Limited, Gnosis Pharmaceuticals Private Limited and 3 more, all in the Pharma industry (Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products).
Mansi Tapan Sanghvi ceased to be Additional Director on 31 Dec 2020. Panna Haresh Sanghvi ceased to be Director on 03 Nov 2020. Mansi Tapan Sanghvi was appointed as Director on 30 Sep 2020. U S Pharma (India) has 11 board changes on record in total.
Yes, U S Pharma (India) is registered as a small enterprise under Udyam registration (number: UDYAM-MH-33-0041439).
U S Pharma (India) has 12 MSME Form 1 returns on record between 2019 and 2024, listing 583 overdue payments to 109 micro and small suppliers. The latest return was filed on 03 May 2024.
U S Pharma (India) can be reached through the website uspharma.in. Its registered office is in Mumbai, Maharashtra, India.